FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2247646252> ?p ?o ?g. }

• W2247646252 endingPage "3166" @default.
• W2247646252 startingPage "3160" @default.
• W2247646252 abstract "Abstract Lym-2 is a murine monoclonal antibody (MoAb) directed towards a human class II molecule variant reactive with both normal and neoplastic human B lymphocytes. Previous studies have shown that signals transmitted by class II molecules that stimulate normal lymphocytes can be inhibitory for B-cell lymphoma growth by signaling activation-induced cell death. Therefore, we sought to evaluate the effects of nonconjugated murine Lym-2 and a human-mouse chimeric Lym-2 (chCLL-1; with murine variable regions and human constant regions) MoAb on the growth of various human lymphomas by using both in vitro and in vivo assays. Cell lines derived from Burkitt's lymphomas, diffuse large cell B-cell lymphomas, anaplastic large-cell lymphomas, and Epstein-Barr virus–induced B-cell lymphomas were incubated with Lym-2 or chCLL-1 in vitro, and effects on proliferation were determined by [3H]-thymidine incorporation. The effects of Lym-2 in vitro were also compared with those of Lym-1, which is a similar MoAb that has been evaluated clinically. After immobilization, which enhances crosslinking of the MoAbs, both Lym-2 and chCLL-1 were capable of directly inhibiting the growth of various lymphoma lines in vitro. These human lymphomas were then transferred into mice with severe combined immunodeficiency to evaluate the efficacy of these MoAbs in vivo. Treatment with either murine Lym-2 or the chimeric chCLL-1 were significantly effective in improving the survival of tumor-bearing mice. These results indicate that stimulation by nonconjugated chCLL-1 may offer a biological approach to the treatment of various human lymphomas." @default.
• W2247646252 created "2016-06-24" @default.
• W2247646252 creator A5014392441 @default.
• W2247646252 creator A5021299258 @default.
• W2247646252 creator A5023265669 @default.
• W2247646252 creator A5036240496 @default.
• W2247646252 creator A5039707350 @default.
• W2247646252 creator A5042070203 @default.
• W2247646252 creator A5051295490 @default.
• W2247646252 creator A5051644740 @default.
• W2247646252 creator A5077143749 @default.
• W2247646252 creator A5079599874 @default.
• W2247646252 creator A5081373240 @default.
• W2247646252 creator A5087985439 @default.
• W2247646252 date "1997-10-15" @default.
• W2247646252 modified "2023-09-28" @default.
• W2247646252 title "Antitumor Effects of Nonconjugated Murine Lym-2 and Human-Mouse Chimeric CLL-1 Monoclonal Antibodies Against Various Human Lymphoma Cell Lines In Vitro and In Vivo" @default.
• W2247646252 cites W111063158 @default.
• W2247646252 cites W1523221134 @default.
• W2247646252 cites W1541624725 @default.
• W2247646252 cites W1572420039 @default.
• W2247646252 cites W1593640213 @default.
• W2247646252 cites W2004051439 @default.
• W2247646252 cites W2044556240 @default.
• W2247646252 cites W2046560815 @default.
• W2247646252 cites W2065347196 @default.
• W2247646252 cites W2078455245 @default.
• W2247646252 cites W2080058454 @default.
• W2247646252 cites W2083424038 @default.
• W2247646252 cites W2100624465 @default.
• W2247646252 cites W221692446 @default.
• W2247646252 cites W226810192 @default.
• W2247646252 cites W2328313834 @default.
• W2247646252 cites W2338368417 @default.
• W2247646252 cites W4238400640 @default.
• W2247646252 cites W4249448676 @default.
• W2247646252 cites W74992319 @default.
• W2247646252 doi "https://doi.org/10.1182/blood.v90.8.3160" @default.
• W2247646252 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9376598" @default.
• W2247646252 hasPublicationYear "1997" @default.
• W2247646252 type Work @default.
• W2247646252 sameAs 2247646252 @default.
• W2247646252 citedByCount "6" @default.
• W2247646252 crossrefType "journal-article" @default.
• W2247646252 hasAuthorship W2247646252A5014392441 @default.
• W2247646252 hasAuthorship W2247646252A5021299258 @default.
• W2247646252 hasAuthorship W2247646252A5023265669 @default.
• W2247646252 hasAuthorship W2247646252A5036240496 @default.
• W2247646252 hasAuthorship W2247646252A5039707350 @default.
• W2247646252 hasAuthorship W2247646252A5042070203 @default.
• W2247646252 hasAuthorship W2247646252A5051295490 @default.
• W2247646252 hasAuthorship W2247646252A5051644740 @default.
• W2247646252 hasAuthorship W2247646252A5077143749 @default.
• W2247646252 hasAuthorship W2247646252A5079599874 @default.
• W2247646252 hasAuthorship W2247646252A5081373240 @default.
• W2247646252 hasAuthorship W2247646252A5087985439 @default.
• W2247646252 hasBestOaLocation W22476462521 @default.
• W2247646252 hasConcept C150903083 @default.
• W2247646252 hasConcept C153911025 @default.
• W2247646252 hasConcept C159654299 @default.
• W2247646252 hasConcept C163864487 @default.
• W2247646252 hasConcept C202751555 @default.
• W2247646252 hasConcept C203014093 @default.
• W2247646252 hasConcept C207001950 @default.
• W2247646252 hasConcept C2778453870 @default.
• W2247646252 hasConcept C2779338263 @default.
• W2247646252 hasConcept C502942594 @default.
• W2247646252 hasConcept C542903549 @default.
• W2247646252 hasConcept C54355233 @default.
• W2247646252 hasConcept C55493867 @default.
• W2247646252 hasConcept C81885089 @default.
• W2247646252 hasConcept C86803240 @default.
• W2247646252 hasConceptScore W2247646252C150903083 @default.
• W2247646252 hasConceptScore W2247646252C153911025 @default.
• W2247646252 hasConceptScore W2247646252C159654299 @default.
• W2247646252 hasConceptScore W2247646252C163864487 @default.
• W2247646252 hasConceptScore W2247646252C202751555 @default.
• W2247646252 hasConceptScore W2247646252C203014093 @default.
• W2247646252 hasConceptScore W2247646252C207001950 @default.
• W2247646252 hasConceptScore W2247646252C2778453870 @default.
• W2247646252 hasConceptScore W2247646252C2779338263 @default.
• W2247646252 hasConceptScore W2247646252C502942594 @default.
• W2247646252 hasConceptScore W2247646252C542903549 @default.
• W2247646252 hasConceptScore W2247646252C54355233 @default.
• W2247646252 hasConceptScore W2247646252C55493867 @default.
• W2247646252 hasConceptScore W2247646252C81885089 @default.
• W2247646252 hasConceptScore W2247646252C86803240 @default.
• W2247646252 hasIssue "8" @default.
• W2247646252 hasLocation W22476462521 @default.
• W2247646252 hasOpenAccess W2247646252 @default.
• W2247646252 hasPrimaryLocation W22476462521 @default.
• W2247646252 hasRelatedWork W1856085589 @default.
• W2247646252 hasRelatedWork W1974845140 @default.
• W2247646252 hasRelatedWork W1999686187 @default.
• W2247646252 hasRelatedWork W2020692772 @default.
• W2247646252 hasRelatedWork W2073840950 @default.
• W2247646252 hasRelatedWork W2366047017 @default.
• W2247646252 hasRelatedWork W2368460920 @default.

• next